Zacks Research Issues Positive Forecast for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities researchers at Zacks Research lifted their Q4 2024 earnings per share (EPS) estimates for United Therapeutics in a note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn $6.04 per share for the quarter, up from their prior estimate of $5.40. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

A number of other equities analysts have also issued reports on the company. Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. HC Wainwright raised their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Bank of America lowered their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. Finally, Wells Fargo & Company upped their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $367.36 on Friday. United Therapeutics has a one year low of $208.62 and a one year high of $417.82. The business has a 50-day simple moving average of $364.39 and a 200-day simple moving average of $330.59. The company has a market cap of $16.40 billion, a PE ratio of 16.13, a P/E/G ratio of 1.05 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the company earned $5.38 EPS. The company’s quarterly revenue was up 22.9% on a year-over-year basis.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 269 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. This trade represents a 67.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Nilda Mesa sold 224 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares in the company, valued at $2,384,215.24. This represents a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,796 shares of company stock valued at $40,936,370 in the last quarter. Company insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. UniSuper Management Pty Ltd lifted its holdings in United Therapeutics by 133.3% in the first quarter. UniSuper Management Pty Ltd now owns 700 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 400 shares during the period. Shell Asset Management Co. grew its stake in shares of United Therapeutics by 81.8% during the first quarter. Shell Asset Management Co. now owns 3,491 shares of the biotechnology company’s stock valued at $802,000 after buying an additional 1,571 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares during the period. Bayesian Capital Management LP purchased a new stake in shares of United Therapeutics during the first quarter valued at $772,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of United Therapeutics in the first quarter worth about $219,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.